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Abstract  
The   identification   of   therapeutic   vulnerabilities   in  mutant  KRAS   tumors   has   proven   difficult   to  
achieve.   Burgess   and   colleagues   recently   reported   in   Cell   that   mutant/wild-­type   Kras   allelic  
dosage   determines   clonal   fitness   and   MEK   inhibitor   sensitivity   in   a   leukemia   model,  
demonstrating  that  KRAS  allelic  imbalance  is  likely  an  important  and  overlooked  variable.      
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The   RAS   family   of   small   GTPases   controls   multiple   signaling   cascades,   including   the  
RAF/MEK/ERK  (MAPK)  and  PI3K/AKT/mTOR  pathways.  Point  mutations   in  codons  G12,  G13  
and  Q61  result  in  the  constitutive  activation  of  the  KRAS  oncogene  and  are  highly  prevalent  in  
epithelial  malignancies,  namely  pancreatic,  colorectal  and  lung  cancers  [1].  KRAS  mutations  are  
also  found  -­-­  albeit  at  a  lower  frequency  -­-­  in  hematological  malignancies,  affecting  approximately  
5%  of  acute  myeloid   leukemias  (AML)  [2,  3].  As  mutant  KRAS  itself  remains  untargetable,   the  
inhibition  of   its  downstream  effectors   represents  an  alternative   therapeutic  strategy   for  mutant  
KRAS  cancer  treatment.  However,  this  approach  has  had  limited  success  to  date  [4,  5],  reflecting  
our   incomplete  understanding  of  mutant  RAS  activity   in   cancer.  Burgess  and  colleagues  now  
show  that  in  murine  AML  and  human  colorectal  cancer  cell   lines,  mutant/wild-­type  (WT)  KRAS  
allelic  balance  dictates  sensitivity  to  MEK  inhibition  [6].  
To  identify  genetic  signatures  of  sensitivity  or  resistance  to  MEK  inhibition,  the  authors  generated  
genetically  diverse  murine  KrasG12D-­driven  AML  in  vivo,  using  retroviral  insertional  mutagenesis.  
Four  independent  primary  AMLs  were  subsequently  transplanted  into  recipient  mice  and  treated  
with  control  vehicle,  or  the  MEK1/2  inhibitor  PD0325901.  While  three  AMLs  showed  only  a  mild  
improvement   in   recipient   survival   following   MEK   inhibition,   one   leukemia   (AML101)   was  
particularly  sensitive   to   this   treatment.  However,  PD0325901  treatment  eventually  selected   for  
the  emergence  of  resistant  clones  within  AML101;;  indeed,  cells  isolated  from  treated  animals  and  
then  subjected  to  subsequent  PD0325901  treatment  exhibited  poorer  treatment  responses  than  
AML101  in  vitro  and  in  vivo.    
Further  characterization  of  the  “super  PD0325901-­responder”  AML101  and  its  derived  resistant  
clone  (AML101-­R)  revealed  Kras  allelic  imbalance  in  both  settings.  Using  a  combination  of  whole  
exome   sequencing   and   fluorescence   in   situ   hybridization   (FISH),   the   authors   showed   that,   in  
contrast  to  the  donor  mouse  (KrasG12D/+),  AML101  was  homozygous  for  the  mutant  KrasG12D  allele,  
with  this  duplication  being  acquired  through  uniparental  disomy.  AML101-­R  cells  also  exhibited  
two  mutant  alleles,  but  in  this  case,  they  were  accompanied  by  a  WT  copy  (G12D:WT  ratio=2:1)  
(Figure  1).  Since   in   the  three  other  AMLs  that  were  only  mildly  sensitive   to  MEK  inhibition  the  
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Kras  WT  allele  was  also  retained  (albeit   to  variable  degrees),   retention  of  WT  Kras  correlated  
directly   with   resistance   to   MEK   inhibition   in   AML.   In   agreement,   the   sensitivity   of   mutant  
homozygous  AML101  cells  to  PD0325901  treatment  in  vitro  was  reduced  upon  overexpression  
of  WT  Kras.  
FISH  analysis  suggested  that  the  PD0325901  resistant  clone  was  present  at  low  frequency  prior  
to   treatment   (approximately   3%).   In   competitive   in   vivo   assays   carried   out   in   the   absence   of  
treatment,  AML101-­R  exhibited  decreased  fitness  relative  to  AML101  explaining  the  preferential  
expansion  of  AML101  prior  to  treatment  and  indicating  that  loss  of  WT  Kras  provides  a  growth  
advantage   to  mutant   homozygous   cells   (Figure   1).   A   growth   inhibitory   role   for  WT  Kras  was  
previously   reported   in   carcinogen-­induced   lung   tumors,   where   despite   the   presence   of  
carcinogen-­induced   Kras   mutations   in   all   lung   lesions,   tumor   development   was   significantly  
accelerated   in  Kras+/-­  mice   relative   to  WT   animals   [7].   By   contrast,   upon  MEK   inhibition,   the  
relative  fitness  of  the  two  AML  clones  was  reversed  (Figure  1),  with  WT  Kras  conferring  a  growth  
advantage   to  AML  cells.  WT  KRAS  was  also  previously  shown   to  provide  a  benefit   to  mutant  
KRAS   colorectal   cancer   cells   by   reducing   mutant-­induced   apoptosis   [8].   Collectively,   these  
findings  highlight  the  context  dependence  and  complexity  of  the  interplay  between  WT  and  mutant  
KRAS  activity  in  tumors.    
Despite   being   significantly   enriched   in   certain   cytogenetic   subtypes,   KRAS   mutations   are  
relatively   uncommon   in   AML   [2].   These   mutations   are,   as   mentioned,   a   common   feature   of  
epithelial  cancers  [1],  prompting  Evangelista  and  Shannon’s  groups  to  examine  the  applicability  
of  their  AML  findings  to  human  epithelial  cancers.  Mutant  KRAS  allelic   imbalance  is  frequently  
found   in  human  pancreatic,   lung  and  colorectal  cancer  cell   lines,  as  well  as   tumor  samples  of  
different  origin  [6,  9].  The  authors  showed  that  colorectal  cancer  cell  lines  with  high  mutant  KRAS  
allelic  frequency  (mutant:WT  allelic  ratio>1)  were  sensitive  to  MEK  inhibition,  while  the  remaining  
cell   lines  displayed  variable   responses   [6].   It   is  unclear  how  WT  Kras  modulates  sensitivity   to  
MEK   inhibition   in  murine  AML   and   human   colorectal   cancer   cell   lines,   and  whether   a   similar  
mechanism  may  be  at  play  in  human  tumors  that  responded  poorly  to  MEK  inhibition  in  clinical  
trials   [4,   10].  However,   since  no   correlation  between  KRAS   status  and  PD0325901   treatment  
   5  
responses   could   be   found   in   pancreatic   and   lung   cancer   cell   lines   [6],   the   therapeutic  
susceptibilities  associated  with  KRAS   allelic   imbalance  are   likely   to  be  context-­  and/or   tissue-­
dependent.    
Oncogene  dosage  is  an  important  emerging  concept  that  takes  into  account  the  effect  of  cancer  
mutations   not   only   from   a   qualitative   perspective   (presence/absence   of   mutation),   but   also  
quantitatively  (copy  gain/loss).  Given  the  high  incidence  of  chromosome  gains/losses  in  human  
cancers   (see   http://cancer.sanger.ac.uk/cosmic),   the   extent   to   which   oncogene   dosage   can  
impact  tumor  development  and  therapy  may  therefore  have  been  underestimated.  In  the  case  of  
KRAS,   there   is  now   increasing  evidence   that   relative  mutant  dosage  can  have  a  major  effect  
across  different  tumor  types.  Indeed,  our  laboratory  recently  showed  that  in  murine  lung  tumor  
models,  mutant  copy  gain  (KrasG12D/G12D  versus  KrasG12D/+)  increases  the  metastatic  potential  of  
tumor  cells  and  rewires  their  glucose  metabolism,  creating  unique  metabolic  dependencies  and  
therapeutic  vulnerabilities.  A  similar  mutant  KRAS  copy  gain  dependent  metabolic  rewiring  was  
observed  in  human  non-­small  cell  lung  cancer  cells  lines  [9].    
Collectively,   these   novel   findings   suggest   that   the   heterogeneity   of   mutant/WT   KRAS   allelic  
content  displayed  by  human  cancers  can  have  important  therapeutic  implications  and  may  have  
contributed  to  the  poor  therapeutic  responses  often  observed  in  the  treatment  of  mutant  KRAS  
tumors   [4,   5].   Stratification   of   KRAS   mutant   tumors   according   to   their   KRAS   allelic   content  
(presence/absence  of  WT  allele,  mutant  and  WT  copy  number)  might  thus  aid  the  identification  
of   therapeutic   vulnerabilities  within   this   heterogeneous  group  of   diseases,   and  may  ultimately  
contribute  to  improved  patient  care.    
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Figure  1:  Differential  Effects  of  Kras  Imbalance  in  AML.  
Murine  AML  cells  with  a  KrasG12D  allele  duplication  that  either  retain  or   lose  the  WT  Kras  copy  
display  differential  growth  capacity  both   in   the  presence  and  absence  of   the  MEK1/2   inhibitor  
PD0325901.  In  particular,  KrasG12D/G12D  cells  exhibit  a  proliferative  advantage  in  the  absence  of  
treatment  but  are  more  sensitive  to  MEK  inhibition  relative  to  cells  that  retain  the  WT  Kras  allele  
[6].    
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